Celsion Corp (AMEX: CLN) announced the completion of its Phase I dose escalation study, using ThermoDox, to treat non-resectable liver ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE